BioGenCell
Netanya
About BioGenCell
BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease. Its technology creates autologous cells, derived from the patients themselves, to repair themselves. Its lead product, BC1, uses the company's technology to treat blood vessel insufficiency that can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, its easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. Its patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products for use in patient treatment.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $16.0M
- Funding stage: Seed
- Last round: Seed (May 2022)
- Website: biogencell.net
- Phone: +972-9-8609248
Industries & Categories
Biotechnology, Diabetes, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/biogencell-154724 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.